HCi Viocare (OTCQB: VICA) is engaged as a diversified health and technology company. Shares of the healthcare technology company are jumping 24.30%, through early trading on Monday, October 9, 2017. Over the past month, HCi Viocare has seen average daily volume of 194,792 shares. However, volume of 183,866 shares or dollar volume of $12,686, has already exchanged hands on Monday.
Shares of HCi Viocare are rallying today, after the company announced that it has appointed Dr. John Doupis, MD, to its scientific advisory board as the Director of Clinical Matters and Diabetes. Dr. Doupis is a former Clinical Research Fellow at Harvard Medical School. Dr. John Doupis’s specialty areas include diabetes and its corresponding complications. Here is the full press release detailing of the newly appointed scientific advisory board member:
HCi Viocare Press Release:
GLASGOW, SCOTLAND–(Marketwired – Oct 9, 2017) – HCi Viocare (“the Company” (OTCQB: VICA)) is delighted to welcome Dr. John Doupis, MD, PhD to its team. Dr. Doupis joins the Scientific Advisory Board assuming the role of Director of Clinical Matters and Diabetes.
Dr. Doupis is a former Clinical Research Fellow of the Joslin Diabetes Center, Harvard Medical School, in Boston, MA, USA, and Scientific partner in Beth Israel Deaconess Foot Center Harvard Medical School, Boston, MA. He is currently directing the Diabetes Division of Iatriko Palaiou Falirou Medical Center as well as, the Internal Medicine and Diabetes Department of the NS Naval Hospital, in Athens, Greece. He is also a Tutor for Diabetes Diploma in Cardiff University Medical School supervising also MSc students.
Dr. Doupis special areas of interest are Diabetes and its complications, especially the Diabetic foot and Obesity. In these fields, he has conducted a substantial number of studies, most of which have been either published in International journals or presented in international congresses. He has also served as a Principal Investigator in multi-center clinical trials. His Doctoral Thesis was also diabetes oriented. He also has special interest in Diabetes related Smart Technology including mobile apps and Telemedicine. In addition, he is a registered reviewer in many major diabetes medical journals and a member of the editorial board of many medical journals. His teaching experience includes courses on Diabetes in Harvard Medical School students in Boston MA as well as subjects of “Internal Medicine” to the students of Athens University Medical School. In addition, he has had the opportunity of tutoring PhD students, at the 1st Dpt of Medicine, Athens University Medical School. He has given numerous lectures in national and international congresses presenting also more than 200 Abstracts.
Sotiris Leontaritis, HCi Viocare’s co-founder and CEO, commented: “Dr. Doupis’ contribution will bring tremendous value to HCi Viocare. He joins at a time where the company is receiving ever-increasing demand for the medical applications of our sensing technology Flexisense™, especially those related to diabetes. With his extensive research and clinical experience Dr. Doupis will contribute to the further advancement of our patent pending technology and will oversee all clinical studies for our diabetic walker and diabetic insole/shoe applications. Under his supervision HCi Viocare also aims to finalize the design and file for a patent, for our novel blood flow and oxygenation monitoring system which is a portable and user friendly blood oxygen concentration and circulation real-time monitoring and visualization device.”
About HCi Viocare
HCi Viocare has two fully owned subsidiaries: 1. HCi Viocare Technologies: developing hardware solutions aiming to empower the user by providing on demand information and enhancing living quality. The R&D center located in Glasgow, Scotland, is working on a large portfolio of cutting edge, revolutionary and disruptive technologies in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices and Sports & Wellbeing. The Company has developed a unique sensing technology with the brand name Flexisense™, which uses a multitude of micro sensors to detect pressure as well as shear that is unique over other sensing technologies. The sensors are wirelessly connected to smart devices providing real time and on demand information. HCi Viocare Technologies works on a licensing business model. 2. HCi Viocare Clinics: creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East.
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements, including but not limited to future developments in the areas of athletic shoes and the information and performance of the Company’s technology in such applications. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company has acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a “smart insole” and its Flexisense TM sensing technology with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
